Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 9/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | TAF1 | P21675 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279744 | 0.86 | PDK2 (0.46) | MAPK13MAPK14PDK2ADRA2AADRA1A | |
| SCHEMBL3277809 | 0.82 | MAPK14 (0.42) | MAPK13MAPK14RAF1CDK8PIK3CG | |
| SCHEMBL379882 | 0.81 | MAPK13 (0.78) | MAPK13MAPK14RAF1 | |
| SCHEMBL3278461 | 0.79 | CDK8 (0.40) | MAPK13MAPK14ADRA2AADRA1ACDK8 | |
| SCHEMBL379826 | 0.76 | MAPK13 (0.86) | MAPK13MAPK14RAF1 | |
| SCHEMBL3277411 | 0.75 | MAPK13 (0.47) | MAPK13MAPK14RAF1 | |
| SCHEMBL2035430 | 0.75 | JAK2 (0.46) | NR1H4PDK2ADRA2AADRA1ACDK8 | |
| SCHEMBL16331828 | 0.73 | MAPK14 (0.51) | MAPK14SMYD2 | |
| SCHEMBL3025015 | 0.72 | FGFR3 (0.49) | CDK8PIK3CGNR4A2 | |
| SCHEMBL380112 | 0.72 | MAPK13 (0.76) | MAPK13MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | MAPK13 37/4885MAPK14 39/4885NR1H4 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.